Interestingly, for patients in ALK‐positive group more multiple bone metastatic sites occurred than double‐negative group, which suggested that advanced ALK‐positive NSCLC patients might have a higher possibility of experiencing SREs in the course of disease, compared with the ALK‐negative patients. This evidence concerns the gene ALK and non-small cell lung carcinoma.